News tagged: U.S. Markets

Tag: U.S. Markets

Indices

January 9, 2026

Dow Rises as Defense Stocks Lead Gains

Investors rotated out of technology shares on Thursday, lifting the Dow Jones Industrial Average while dragging down the Nasdaq Composite. The Russ...

Gold Slips as Investors Weigh US Data and Rising Geopolitical Risks

Commodities

January 8, 2026

Gold Slips as Investors Weigh US Data and Rising Geopolitical Risks

Gold prices eased to around $4,440 per ounce on Thursday, extending losses from the prior session as investors digested mixed U.S. economic signals...

Dow Slides Over 450 Points as S&P 500 Retreats From Record

Indices

January 8, 2026

Dow Slides Over 450 Points as S&P 500 Retreats From Record

U.S. equities retreated from record levels on Wednesday as early-year momentum faded in some of the market’s strongest sectors. The S&...

Stock Market

January 7, 2026

Energy Stocks Lag as S&P 500 Rises

U.S. equities traded higher Tuesday, with the S&P 500 posting gains, but energy stocks sharply underperformed. The S&P 500 Energy Sector...

Why Saving for Retirement in Your 20s and 30s Matters More Than You Think

Market Insights

January 7, 2026

Why Saving for Retirement in Your 20s and 30s Matters More Than You Think

If you’re in your 20s or early 30s, retirement may feel like a distant concern—something to worry about later. You’re focused on ...

Dow Hits Fresh Record, Closes Above 49,000

Indices

January 7, 2026

Dow Hits Fresh Record, Closes Above 49,000

U.S. stocks surged on Tuesday as investors largely brushed aside geopolitical volatility following the U.S. capture of Venezuelan leader Nicol&aacu...

Market Insights

January 6, 2026

Why Silver’s Set-Up Looks Explosive

Silver is no longer “gold’s understudy.” Its role in the global economy has undergone a complete transformation, driven by the el...

Zenas BioPharma Shares Plunge 55% Despite ‘Positive’ Phase 3 Trial Results

Stock Market

January 6, 2026

Zenas BioPharma Shares Plunge 55% Despite ‘Positive’ Phase 3 Trial Results

Zenas BioPharma (ZBIO) stunned investors on Monday after its shares plunged 55%, even as the company reported what it described as “positive&...